{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:54:04Z","timestamp":1791849244453,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2025ZD0544300"],"award-info":[{"award-number":["2025ZD0544300"]}]},{"name":"Beijing High-Level Innovation and Entrepreneurship Talent Support Program leading talent projects","award":["G202512029"],"award-info":[{"award-number":["G202512029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CUE domain-containing 2 (CUEDC2) regulates ubiquitin-mediated protein turnover, cell-cycle progression, and inflammatory signaling, but its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. DLBCL is the most common aggressive non-Hodgkin lymphoma, and a substantial proportion of patients develop relapsed or refractory disease. Here, by integrating clinical bioinformatics, immunohistochemistry, and functional studies in DLBCL cell lines, we demonstrate that CUEDC2 is overexpressed in DLBCL and is associated with advanced disease stage and poor prognosis. Mechanistically, proteomic and ubiquitination analyses revealed that CUEDC2 interacts with the protein phosphatase 2A (PP2A) regulatory subunit B55 and promotes its ubiquitination-associated proteasomal degradation, accompanied by activation of NF-\u03baB and mTOR signaling. Rescue studies support the role of PP2A-B55 as a downstream effector contributing to CUEDC2-associated proliferation and chemoresistance, and isoform-specific experiments identify PP2A-B55\u03b2 as a preferentially regulated isoform. In addition, CUEDC2 knockdown in macrophages promoted M1-like polarization, enhanced phagocytosis, and supported CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell activation and lymphoma cell apoptosis in vitro, without a detectable change in PP2A-B55 protein abundance. These immune effects were accompanied by changes in cellular metabolism and histone lactylation, although their causal relationships remain unresolved. Together, these findings support a tumor cell-intrinsic CUEDC2\u2013PP2A-B55\u03b2\u2013NF-\u03baB\/mTOR axis in DLBCL and suggest a potentially distinct immunomodulatory role for CUEDC2. Further mechanistic studies and in vivo validation are required to establish its therapeutic potential.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00626-x","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:22:14Z","timestamp":1791847334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55\u03b2 degradation and shapes macrophage-mediated immune responses"],"prefix":"10.1186","volume":"7","author":[{"given":"Li-Jie","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Zheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-914X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"1","key":"626_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100750","volume":"8","author":"T Melchardt","year":"2023","unstructured":"Melchardt T, Egle A, Greil R. How I treat diffuse large B-cell lymphoma. ESMO Open. 2023;8(1):100750. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100750.","journal-title":"ESMO Open"},{"issue":"2","key":"626_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2016-02-696856","volume":"128","author":"JM Matthews","year":"2016","unstructured":"Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, et al. Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood. 2016;128(2):239\u201348. https:\/\/doi.org\/10.1182\/blood-2016-02-696856.","journal-title":"Blood"},{"issue":"9","key":"626_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70207","volume":"9","author":"C Thieblemont","year":"2025","unstructured":"Thieblemont C, Gomes Da Silva M, Lepp\u00e4 S, Lenz G, Cottereau AS, Fox C, et al. Large B-cell lymphoma (LBCL): EHA clinical practice guidelines for diagnosis, treatment, and follow-up. Hemasphere. 2025;9(9):e70207. https:\/\/doi.org\/10.1002\/hem3.70207.","journal-title":"Hemasphere"},{"issue":"16","key":"626_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2020005002","volume":"135","author":"BD Cheson","year":"2020","unstructured":"Cheson BD. Predicting the future for DLBCL. Blood. 2020;135(16):1308\u20139. https:\/\/doi.org\/10.1182\/blood.2020005002.","journal-title":"Blood"},{"issue":"9","key":"626_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13238-011-1089-z","volume":"2","author":"J Man","year":"2011","unstructured":"Man J, Zhang X. CUEDC2: an emerging key player in inflammation and tumorigenesis. Protein Cell. 2011;2(9):699\u2013703. https:\/\/doi.org\/10.1007\/s13238-011-1089-z.","journal-title":"Protein Cell"},{"issue":"6","key":"626_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/emboj\/cdg140","volume":"22","author":"SC Shih","year":"2003","unstructured":"Shih SC, Prag G, Francis SA, Sutanto MA, Hurley JH, Hicke L. A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J. 2003;22(6):1273\u201381. https:\/\/doi.org\/10.1093\/emboj\/cdg140.","journal-title":"EMBO J"},{"issue":"11","key":"626_CR7","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41417-022-00494-x","volume":"29","author":"S Roy","year":"2022","unstructured":"Roy S, Saha S, Dhar D, Chakraborty P, Singha Roy K, Mukherjee C, et al. Molecular crosstalk between CUEDC2 and ER\u03b1 influences the clinical outcome by regulating mitosis in breast cancer. Cancer Gene Ther. 2022;29(11):1697\u2013706. https:\/\/doi.org\/10.1038\/s41417-022-00494-x.","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"626_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41419-018-0812-6","volume":"9","author":"QY Wu","year":"2018","unstructured":"Wu QY, Zhu YY, Liu Y, Wei F, Tong YX, Cao J, et al. CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia. Cell Death Dis. 2018;9(7):774. https:\/\/doi.org\/10.1038\/s41419-018-0812-6.","journal-title":"Cell Death Dis"},{"issue":"5","key":"626_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41419-020-2562-5","volume":"11","author":"JW Kim","year":"2020","unstructured":"Kim JW, Oh SH, Lee MN, Song JH, Jeong BC, Yang JW, et al. CUEDC2 controls osteoblast differentiation and bone formation via SOCS3-STAT3 pathway. Cell Death Dis. 2020;11(5):344. https:\/\/doi.org\/10.1038\/s41419-020-2562-5.","journal-title":"Cell Death Dis"},{"issue":"45","key":"626_CR10","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1038\/s41388-020-01466-x","volume":"39","author":"M Mu","year":"2020","unstructured":"Mu M, Niu W, Zhang X, Hu S, Niu C. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN\/AKT\/p21 pathway. Oncogene. 2020;39(45):6879\u201392. https:\/\/doi.org\/10.1038\/s41388-020-01466-x.","journal-title":"Oncogene"},{"issue":"5","key":"626_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2741\/4759","volume":"24","author":"JB Xiao","year":"2019","unstructured":"Xiao JB, Leng AM, Zhang YQ, Wen Z, He J, Ye GN. CUEDC2: multifunctional roles in carcinogenesis. Front Biosci (Landmark Ed). 2019;24(5):935\u201346. https:\/\/doi.org\/10.2741\/4759.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"5","key":"626_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.15252\/embr.201643617","volume":"18","author":"X Zhong","year":"2017","unstructured":"Zhong X, Tian S, Zhang X, Diao X, Dong F, Yang J, et al. CUE domain-containing protein 2 promotes the Warburg effect and tumorigenesis. EMBO Rep. 2017;18(5):809\u201325. https:\/\/doi.org\/10.15252\/embr.201643617.","journal-title":"EMBO Rep"},{"key":"626_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2025.119408","volume":"342","author":"X Deng","year":"2025","unstructured":"Deng X, Jiao Y, Hao H, Guo Z, An G, Zhang W, et al. Dandelion extract suppresses the stem-like properties of triple-negative breast cancer cells by regulating CUEDC2\/\u03b2-catenin\/OCT4 signaling axis. J Ethnopharmacol. 2025;342:119408. https:\/\/doi.org\/10.1016\/j.jep.2025.119408.","journal-title":"J Ethnopharmacol"},{"issue":"13","key":"626_CR14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1182\/blood.2020006784","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138(13):1110\u20139. https:\/\/doi.org\/10.1182\/blood.2020006784.","journal-title":"Blood"},{"issue":"1","key":"626_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175. https:\/\/doi.org\/10.1186\/s13045-020-01011-z.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"626_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu W, Berning P, Erdmann T, Grau M, Bettazov\u00e1 N, Zapukhlyak M, et al. MTOR inhibition amplifies the anti-lymphoma effect of PI3K\u03b2\/\u03b4 blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37(1):178\u201389. https:\/\/doi.org\/10.1038\/s41375-022-01749-0.","journal-title":"Leukemia"},{"issue":"Pt A","key":"626_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111125","volume":"125","author":"G Gao","year":"2023","unstructured":"Gao G, Xue Q, He J, Wu M, Jiang Y, Li Q, et al. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K\/AKT\/mTOR signaling pathway. Int Immunopharmacol. 2023;125(Pt A):111125. https:\/\/doi.org\/10.1016\/j.intimp.2023.111125.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"626_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom10111586","volume":"10","author":"P Goguet-Rubio","year":"2020","unstructured":"Goguet-Rubio P, Amin P, Awal S, Vigneron S, Charrasse S, Mechali F, et al. PP2A-B55 holoenzyme regulation and cancer. Biomolecules. 2020;10(11):E1586. https:\/\/doi.org\/10.3390\/biom10111586.","journal-title":"Biomolecules"},{"issue":"1","key":"626_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41388-021-02068-x","volume":"41","author":"P Amin","year":"2022","unstructured":"Amin P, Awal S, Vigneron S, Roque S, Mechali F, Labb\u00e9 JC, et al. PP2A-B55: substrates and regulators in the control of cellular functions. Oncogene. 2022;41(1):1\u201314. https:\/\/doi.org\/10.1038\/s41388-021-02068-x.","journal-title":"Oncogene"},{"issue":"16","key":"626_CR20","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1182\/bloodadvances.2022007493","volume":"6","author":"AR Colombo","year":"2022","unstructured":"Colombo AR, Hav M, Singh M, Xu A, Gamboa A, Lemos T, et al. Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma. Blood Adv. 2022;6(16):4675\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2022007493.","journal-title":"Blood Adv"},{"issue":"1","key":"626_CR21","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/s41467-024-46220-z","volume":"15","author":"M Liu","year":"2024","unstructured":"Liu M, Bertolazzi G, Sridhar S, Lee RX, Jaynes P, Mulder K, et al. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma. Nat Commun. 2024;15(1):2113. https:\/\/doi.org\/10.1038\/s41467-024-46220-z.","journal-title":"Nat Commun"},{"issue":"2","key":"626_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3324\/haematol.2015.124008","volume":"100","author":"R Kridel","year":"2015","unstructured":"Kridel R, Steidl C, Gascoyne RD. Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica. 2015;100(2):143\u20135. https:\/\/doi.org\/10.3324\/haematol.2015.124008.","journal-title":"Haematologica"},{"issue":"22","key":"626_CR23","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1182\/bloodadvances.2024013699","volume":"8","author":"S Kim","year":"2024","unstructured":"Kim S, Jeong H, Ahn HK, Han B, Lee KC, Song YK, et al. Increased CCL2\/CCR2 axis promotes tumor progression by increasing M2 macrophages in MYC\/BCL2 double-expressor DLBCL. Blood Adv. 2024;8(22):5773\u201388. https:\/\/doi.org\/10.1182\/bloodadvances.2024013699.","journal-title":"Blood Adv"},{"key":"626_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112447","volume":"137","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Yang Y, Zeng Y, Chen K, Zhang Q, Wang L, et al. The significance of CD8+ tumor-infiltrating lymphocytes exhaustion heterogeneity and its underlying mechanism in diffuse large B-cell lymphoma. Int Immunopharmacol. 2024;137:112447. https:\/\/doi.org\/10.1016\/j.intimp.2024.112447.","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"626_CR25","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1042\/cs20201367","volume":"135","author":"DL Brautigan","year":"2021","unstructured":"Brautigan DL, Farrington C, Narla G. Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clin Sci (Lond). 2021;135(13):1545\u201356. https:\/\/doi.org\/10.1042\/cs20201367.","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"626_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s44318-024-00054-z","volume":"43","author":"B Lacroix","year":"2024","unstructured":"Lacroix B, Vigneron S, Labb\u00e9 JC, Pintard L, Lionne C, Labesse G, et al. Increases in cyclin A\/Cdk activity and in PP2A-B55 inhibition by FAM122A are key mitosis-inducing events. EMBO J. 2024;43(6):993\u20131014. https:\/\/doi.org\/10.1038\/s44318-024-00054-z.","journal-title":"EMBO J"},{"issue":"18","key":"626_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186642","volume":"21","author":"SH Seo","year":"2020","unstructured":"Seo SH, Kim SG, Shin JH, Ham DW, Shin EH. Toxoplasma GRA16 inhibits NF-\u03baB activation through PP2A-B55 upregulation in non-small-cell lung carcinoma cells. Int J Mol Sci. 2020;21(18):E6642. https:\/\/doi.org\/10.3390\/ijms21186642.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"626_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.cub.2020.11.058","volume":"31","author":"J Kamenz","year":"2021","unstructured":"Kamenz J, Gelens L, Ferrell JE. Bistable, biphasic regulation of PP2A-B55 accounts for the dynamics of mitotic substrate phosphorylation. Curr Biol. 2021;31(4):794-808.e6. https:\/\/doi.org\/10.1016\/j.cub.2020.11.058.","journal-title":"Curr Biol"},{"issue":"2","key":"626_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022110833","volume":"42","author":"B Sanz-Castillo","year":"2023","unstructured":"Sanz-Castillo B, Hurtado B, Vara-Ciruelos D, El Bakkali A, Hermida D, Salvador-Barbero B, et al. The MASTL\/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. EMBO J. 2023;42(2):e110833. https:\/\/doi.org\/10.15252\/embj.2022110833.","journal-title":"EMBO J"},{"issue":"5","key":"626_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114155","volume":"43","author":"KH Chia","year":"2024","unstructured":"Chia KH, Takaki H, Fujimitsu K, Darling S, Zou J, Rappsilber J, et al. CDK1-PP2A-B55 interplay ensures cell cycle oscillation via Apc1-loop300. Cell Rep. 2024;43(5):114155. https:\/\/doi.org\/10.1016\/j.celrep.2024.114155.","journal-title":"Cell Rep"},{"issue":"7403","key":"626_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352. https:\/\/doi.org\/10.1038\/nature10983.","journal-title":"Nature"},{"issue":"7","key":"626_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cancergen.2011.05.002","volume":"204","author":"Y Cheng","year":"2011","unstructured":"Cheng Y, Liu W, Kim ST, Sun J, Lu L, Sun J, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011;204(7):375\u201381. https:\/\/doi.org\/10.1016\/j.cancergen.2011.05.002.","journal-title":"Cancer Genet"},{"issue":"4","key":"626_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12185-012-1171-1","volume":"96","author":"Y Kamada","year":"2012","unstructured":"Kamada Y, Sakata-Yanagimoto M, Sanada M, Sato-Otsubo A, Enami T, Suzukawa K, et al. Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis. Int J Hematol. 2012;96(4):492\u2013500. https:\/\/doi.org\/10.1007\/s12185-012-1171-1.","journal-title":"Int J Hematol"},{"issue":"11","key":"626_CR34","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/leu.2011.146","volume":"25","author":"PP Ruvolo","year":"2011","unstructured":"Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, et al. Low expression of PP2A regulatory subunit B55\u03b1 is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia. 2011;25(11):1711\u20137. https:\/\/doi.org\/10.1038\/leu.2011.146.","journal-title":"Leukemia"},{"issue":"7","key":"626_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/2159-8290.cd-23-0216","volume":"14","author":"MH Dias","year":"2024","unstructured":"Dias MH, Friskes A, Wang S, Fernandes Neto JM, van Gemert F, Mourragui S, et al. Paradoxical activation of oncogenic signaling as a cancer treatment strategy. Cancer Discov. 2024;14(7):1276\u2013301. https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0216.","journal-title":"Cancer Discov"},{"issue":"8","key":"626_CR36","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/0008-5472.can-15-2119","volume":"76","author":"AL Hein","year":"2016","unstructured":"Hein AL, Seshacharyulu P, Rachagani S, Sheinin YM, Ouellette MM, Ponnusamy MP, et al. PR55\u03b1 subunit of protein phosphatase 2A supports the tumorigenic and metastatic potential of pancreatic cancer cells by sustaining hyperactive oncogenic signaling. Cancer Res. 2016;76(8):2243\u201353. https:\/\/doi.org\/10.1158\/0008-5472.can-15-2119.","journal-title":"Cancer Res"},{"issue":"1","key":"626_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"626_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6208-x","volume":"19","author":"YL Li","year":"2019","unstructured":"Li YL, Shi ZH, Wang X, Gu KS, Zhai ZM. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count. BMC Cancer. 2019;19(1):1049. https:\/\/doi.org\/10.1186\/s12885-019-6208-x.","journal-title":"BMC Cancer"},{"issue":"2","key":"626_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100(2):238\u201345. https:\/\/doi.org\/10.3324\/haematol.2014.113472.","journal-title":"Haematologica"},{"issue":"1","key":"626_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36\u201350. https:\/\/doi.org\/10.1016\/j.cmet.2019.06.001.","journal-title":"Cell Metab"},{"issue":"6","key":"626_CR41","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.celrep.2014.05.007","volume":"7","author":"Y Chen","year":"2014","unstructured":"Chen Y, Wang SX, Mu R, Luo X, Liu ZS, Liang B, et al. Dysregulation of the miR-324-5p-CUEDC2 axis leads to macrophage dysfunction and is associated with colon cancer. Cell Rep. 2014;7(6):1982\u201393. https:\/\/doi.org\/10.1016\/j.celrep.2014.05.007.","journal-title":"Cell Rep"},{"issue":"20","key":"626_CR42","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135(20):1759\u201371. https:\/\/doi.org\/10.1182\/blood.2019003535.","journal-title":"Blood"},{"issue":"4","key":"626_CR43","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.15619","volume":"185","author":"D Painter","year":"2019","unstructured":"Painter D, Barrans S, Lacy S, Smith A, Crouch S, Westhead D, et al. Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK\u2019s population-based Haematological Malignancy Research Network. Br J Haematol. 2019;185(4):781\u20134. https:\/\/doi.org\/10.1111\/bjh.15619.","journal-title":"Br J Haematol"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00626-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:22:15Z","timestamp":1791847335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00626-x","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal procedures were performed in compliance with the animal care guidelines approved by the Institutional Animal Care and Use Committees of Hangzhou Yingchi Biotechnology Co., Ltd (INCH-IACUC-2023\u201312-085). The retrospective observational study involving patient samples and clinical data was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (approval no. TREC2025-KY207). The requirement for informed consent for the retrospective use of these samples and data was waived by the Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"208"}}